A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies
- 1 December 2008
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 67 (12) , 1670-1677
Abstract
Objective: To investigate the effect of the tumour necrosis factor (TNF) blocking agent infliximab in patients with treatment-resistant inflammatory myopathies. Methods: A total of 13 patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 4 infliximab infusions (5 mg/kg body weight) over 14 weeks. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS), and MRI. Repeated muscles biopsies were investigated for cellular infiltrates, major histocompatibility complex (MHC) class I and II, TNF, interleukin (IL)1α, IL6, high mobility group box chromosomal protein 1 (HMGB-1), interferon γ (IFNγ), myxovirus resistance protein A (MxA) and membrane attack complex (MAC) expression. Type I IFN activity was analysed in sera. Results: Nine patients completed the study. Three patients discontinued due to adverse events and one due to a discovered malignancy. Three of the completers improved by ⩾20% in three or more variables of the disease activity core set, four were unchanged and two worsened ⩾30%. No patient improved in muscle strength by manual muscle test. At baseline, two completers had signs of muscle inflammation by MRI, and five at follow-up. T lymphocytes, macrophages, cytokine expression and MAC deposition in muscle biopsies were still evident after treatment. Type I IFN activity was increased after treatment. Conclusions: Infliximab treatment was not effective in refractory inflammatory myopathies. In view of radiological and clinical worsening, and activation of the type I IFN system in several cases, infliximab is not an alternative treatment in patients with treatment-resistant myositis.Keywords
This publication has 37 references indexed in Scilit:
- Augmented interferon‐α pathway activation in patients with Sjögren's syndrome treated with etanerceptArthritis & Rheumatism, 2007
- Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositisArthritis & Rheumatism, 2007
- High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosusGenes & Immunity, 2007
- Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patientsAnnals of the Rheumatic Diseases, 2006
- Treatment of Dermatomyositis and Polymyositis with Anti-Tumor Necrosis Factor-α: Long-Term Follow-UpEuropean Neurology, 2004
- Refractory polymyositis responding to infliximabRheumatology, 2004
- Down‐regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroidsArthritis & Rheumatism, 2004
- Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1Rheumatology, 2004
- Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositisArthritis & Rheumatism, 2004
- Polymyositis associated with infliximab treatment for rheumatoid arthritisRheumatology, 2003